Methylphenidate-Oxoacid Conjugates, Processes of Making and Using the Same
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2012/048641, filed Jul 27, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,079,928 | Methylphenidate-Oxoacid Conjugates, Processes of Making and Using the Same In force · High confidence | Commave Therapeutics S.A. | In force | High confidence | ||
| US 9,453,037 | Methylphenidate-Prodrugs, Processes of Making and Using the Same In force · High confidence | Commave Therapeutics S.A. | In force | High confidence | ||
| US 10,231,960 | Methylphenidate-Prodrugs, Processes of Making and Using the Same In force · High confidence | Commave Therapeutics S.A. | In force | High confidence | ||
| Application 16/244,460 | Methylphenidate-Prodrugs, Processes of Making and Using the Same Abandoned Abandoned May 13, 2020 | Commave Therapeutics S.A. | Abandoned | Abandoned May 13, 2020 |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Commave Therapeutics S.A..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.